The peptide does not bind to a known receptor with high specificity, which complicates mechanistic classification
It should be handled only by qualified professionals and used strictly for research purposes according to applicable laws, safety standards, and laboratory guidelines
The FDA's own scientists had already reviewed all of this data, and recommended against it because of a lack of evidence: "Accordingly, we propose not adding BPC-157 (free base) or BPC-157 acetate to the 503A Bulks List" [12]
Frontiers in Pharmacology, 13, 1026182
39.9% with placebo), with nausea, vomiting, and diarrhea peaking during dose escalation and declining thereafter, whereas constipation remained relatively constant